PS1344 PHASE 1/2 STUDY OF DSP-7888 IN PATIENTS WITH HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AFTER FAILURE OF AZACITIDINE (AZA) THERAPY

Autor:	Y. Miyazaki, Kensuke Usuki, T. Naoe, N. Aotsuka, S. Sugimoto, T. Nakazato, A. Watanabe, E. Koga-Yamakawa, Masahiro Kizaki, H. Iwasaki, J. Fujita, Itaru Matsumura, Y. Heike, K. Akashi, Y. Ueda, Naohiro Sekiguchi
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine Myelodysplastic syndromes Azacitidine medicine In patient Hematology business medicine.disease medicine.drug
Zdroj:	HemaSphere. 3:613-614
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000563656.45660.98
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::27007b65879bcb237890610233bbe043 https://doi.org/10.1097/01.hs9.0000563656.45660.98 Zobrazit plný text záznamu Plný text